Taylor A, Ziffer J A, Eshima D
Department of Radiology, Emory University School of Medicine, Atlanta, Georgia 30322.
Clin Nucl Med. 1990 Jun;15(6):371-8. doi: 10.1097/00003072-199006000-00001.
Tc-99m mercaptoacetyltriglycine (MAG3) is a new Tc-99m renal agent that compares favorably to I-131 Hippuran in animal models, normal volunteers, and patients. Based on the fact that Tc-99m MAG3 has a much more rapid clearance than Tc-99m DTPA and a smaller volume of distribution, it was postulated that the image quality of Tc-99m MAG3 studies should be superior to scans obtained using Tc-99m DTPA, particularly in patients with impaired renal function. To test this hypothesis, Tc-99m DTPA and MAG3 images were obtained in three transplant patients during periods of stable but impaired renal function. In one study, the Tc-99m DTPA study was potentially misleading, whereas the Tc-99m MAG3 examination assessed the clinical situation correctly. In all three cases, the Tc-99m MAG3 images were superior.
锝-99m 巯基乙酰三甘氨酸(MAG3)是一种新型的锝-99m 肾显像剂,在动物模型、正常志愿者及患者中与碘-131 马尿酸相比具有优势。基于锝-99m MAG3 比锝-99m 二乙三胺五乙酸(DTPA)清除更快且分布容积更小这一事实,推测锝-99m MAG3 检查的图像质量应优于使用锝-99m DTPA 获得的扫描图像,尤其是在肾功能受损的患者中。为验证这一假设,在三名移植患者肾功能稳定但受损期间获取了锝-99m DTPA 和 MAG3 图像。在一项研究中,锝-99m DTPA 检查可能产生误导,而锝-99m MAG3 检查正确评估了临床情况。在所有三例中,锝-99m MAG3 图像均更优。